NIH PA-27-101: SBIR Phase IIB Strategic Breakthrough Award

NIH PA-27-101: SBIR Phase IIB Strategic Breakthrough Award

The NIH Phase IIB Strategic Breakthrough program is a late-stage commercialization bridge award within the NIH SBIR/STTR ecosystem. It was posted on May 28, 2026 and, for this round, accepts the first deadline opening on August 5, 2026. It is designed for small businesses that already reached the NIH SBIR/STTR Phase II stage and now face a capital gap before a product can be commercially viable.

The NOFO is explicit that this is a second Phase II opportunity, not a replacement for early-stage SBIR or STTR funding. In NIH language, the focus is on follow-on research and development with stronger commercial potential, where additional funding can de-risk advanced work after Phase II completion.

Key Details

At least one of the participating Institutes or Centers (NICHD, NIAAA, NCI, NIDDK, NIGMS, NIAID, NHLBI, NIMH, NINDS, etc.) can host the application depending on programmatic fit.

What this award is really for

You should treat PA-27-101 as a commercial bridge instrument rather than exploratory grant funding. The public text says the program closes the “Valley of Death” between Phase II and commercialization and supports late-stage development for products that are close to market impact.

The practical interpretation is simple:

• You should already have a technical base and a history of NIH SBIR/STTR Phase II funding.
• You should be trying to move from validated feasibility into scale, regulatory preparation, or commercialization execution.
• You should be able to demonstrate that your next work phase needs more than existing non-federal funding can cover.

This is not the right mechanism for greenfield ideas without Phase II grounding. It is similarly not designed for non-U.S. entities without SBIR/STTR continuity. The NOFO is explicit about applicant continuity and scope: “previously funded NIH SBIR/STTR Phase II recipients.”

The program statement also notes that commercial potential is important. For this reason, applications with strong commercialization milestones, a realistic commercialization plan, and realistic cost structure align better than purely curiosity-driven proposals. Teams that submit only technical language with weak commercialization logic usually fail to stand out during review.

Who this opportunity is built for

This call is for a narrow profile of applicants:

1. U.S.-based small businesses that qualify as SBCs under SBA rules.
2. Firms with prior NIH SBIR or STTR Phase II award history.
3. Ventures preparing a second large funding tranche to complete a translational path toward adoption.
4. Teams that can credibly secure non-SBIER/STTR matching capital.

The 100% matching requirement is unusual at this scale. This is not a typical “federal match plus internal contribution” setup; the NOFO requires documented matching resources equivalent to NIH-supported costs. That means your commercial story and the investor/developer commitments must be documented through the application and, later, by NIH review if the match claim is challenged.

The call also permits renewal, resubmission, and revision format under NIH SBIR Phase IIB rules, but it is not a generic open market for new startup teams with no NIH small-business history.

Eligibility: what matters before you write a word

The eligibility section is precise and deserves strict interpretation.

Organization level

Only U.S. small business concerns that have previously received NIH SBIR or STTR Phase II can apply. If your company has never completed a Phase II award in this NIH pathway, the filing is structurally misaligned.

The NOFO references SBA definitions for SBCs: for-profit, U.S. location, tax/economic contribution, ownership controls, and ≤500 employees. It also allows ownership and joint venture structures with detailed requirements (including private-entity limits in some structures). If your cap table or JV structure is complex, treat legal review as mandatory before concept paper drafting.

Program continuity

A key line in eligibility language says applicants should submit Phase IIB within the first six due dates after Phase II award expiration. If your SBIR/STTR Phase II period is nearing end, this introduces an immediate timeline constraint even if you still have technical runway.

Match requirement

The program requires not less than 100% third-party matching funds from:

• new private capital (new company, VC, or other investor), or
• new government funding other than NIH SBIR/STTR Phase I/II, or
• a combination of both.

This is not optional phrasing. The application must describe and evidence a real, non-NIH source.

Clinical trial rules and exclusions

Clinical trials may be optional in principle, but several NIH components listed in the opportunity do not accept clinical trials for this NOFO. If your project is trial-heavy, verify compatibility with the receiving Institute/Center early; mismatch here can fail responsiveness.

Practical consequence

Most teams underestimate the eligibility pass/fail boundary. This opportunity is less about writing quality at first; it is mostly about whether the applicant and structure satisfy the rules before review starts.

Awards, funding structure, and financial reality

The NOFO sets Total funding support ... may not exceed $30,000,000 for Phase IIB awards. It also says the number of awards depends on appropriations and competitive merit. That means award sizes can vary by Institute/Center and project readiness.

Institute/Center-specific budget caps are also listed and differ by component. For planning, use the most conservative interpretation: proposal budgets must fit your assigned IC cap and show compliance with that IC’s limits, while remaining commercially credible.

Project period can be up to 4 years by statutory rule. This is significantly longer than Phase II follow-on work expectations in some agencies and implies NIH is explicitly supporting meaningful development windows.

Because this is a commercialization bridge, budget justification should be tied to development milestones, not broad research curiosity:

• late-stage prototyping,
• regulatory readiness evidence,
• manufacturing or scalability planning,
• market and commercialization pathway costs,
• post-award obligations tied to the match.

A frequent strategy mistake is proposing research expansion unrelated to commercialization deliverables and expecting match-backed execution logic to be accepted anyway. The review framing around strategic breakthrough is much closer to translational acceleration than basic science discovery.

When this rounds close: timeline planning

The table on the page shows recurring windows: September 5, January 5, and April 5 across 2026 to 2029, with review and earliest start dates staggered accordingly. The NOFO also lists an expiration date of April 6, 2029, while the recurring due dates remain the active filing path while the solicitation is open.

For current planning around 2026:

• Earliest submission opening: 2026-08-05.
• First practical due date: 2026-09-05 (5:00 PM local organization time).
• Next cycles: 2027-01-05 and 2027-04-05, etc., if still pursuing or if your team strategy prefers later windows.

Because your company may already need time to secure matching capital, teams often use the next window strategically. However, because review and council timing pushes earliest starts into the same quarter and because late applications are not accepted, teams should not “wait for perfect completion” if the first date aligns with current data and funding readiness.

Application route and system setup

The NOFO gives three submission routes:

1. NIH ASSIST (recommended workflow path for many NIH awards).
2. Institutional S2S submission to Grants.gov with eRA Commons tracking.
3. Grants.gov Workspace to Grants.gov for forms, with eRA Commons tracking.

From a compliance standpoint, this is a standard NIH SBIR/STTR workflow, but the strategic burden is mostly in the preparatory evidence before submission:

• Confirm all registrations are current and complete before the submission window.
• Ensure the company is still documented as meeting all SBA small-business conditions.
• Prepare the SBIR/STTR Information Form components, especially commercialization plan and finance plan.
• Build explicit, auditable match evidence.
• Capture prior Phase II award identifiers and show continuity from prior milestones.
• Verify whether your target IC will accept the scope you are proposing (especially if it includes clinical trial elements).

The NOFO also supports renewals/resubmissions/revisions within permitted pathways. If this is a renewal scenario, treat your change history and reviewer feedback history as evidence. If this is a first Phase IIB filing, show why your current work differs materially from Phase II and how the gap is being bridged.

What reviewers care about in this mechanism

This section is where many teams fail: they write as if they are bidding for another early research award while the call is explicitly for a commercialization bridge.

Review for this call is still peer-review informed and goes through scientific merit channels and administrative compliance. But the text emphasizes that commercial potential is heavily weighted in decision quality.

A strong application usually demonstrates:

• a clear reason why a follow-on NIH support is required rather than private follow-on capital alone,
• evidence that the technology can cross from Phase II proof to commercialization,
• strong execution architecture across team, timelines, and budget,
• realistic commercialization assumptions, including customer pathway or adoption logic,
• compliance that avoids avoidable administrative corrections.

In practice, teams that win or make the discussion cut usually present “Phase II+1” logic clearly:

1. What exactly was proven in Phase II,
2. What remains unproven for product adoption,
3. Why this unproven work cannot be delayed or de-risked without this specific follow-on instrument.

How this differs from standard SBIR/STTR or other NIH mechanisms

This is a common source of confusion. PI-led teams that are successful in Phase II often assume Phase IIB is just another NIH tranche. It is not. The explicit match requirement changes incentive design. Also, the technical bar often increases because the commercialization question is central.

If you compare with earlier-stage SBIR/STTR awards:

• Phase I: feasibility,
• Phase II: scale and development,
• Phase IIB in this NOFO: commercialization bridge with explicit market and development financing discipline.

So while scientific excellence matters, the grant is structurally closer to “proof-to-commercialization conversion” than to “new scientific direction exploration.”

Common mistakes to avoid

1. Applying without a completed, qualifying NIH SBIR/STTR Phase II history. That fails the fundamental premise.

2. Underestimating match documentation. The NOFO requires 100% match; saying “will secure private capital” without concrete evidence is not the same as a matched application.

3. Using a generic PI-only narrative. This mechanism is business/technical commercialization by design; the commercialization plan section must be more than a paragraph.

4. Submitting with clinical trial assumptions that conflict with IC constraints. The NOFO lists organizations that do not accept clinical trials under this mechanism.

5. Ignoring Institute or Center-specific budget ceilings. Applicants must respect IC-specific maximums and not treat the $30M statement as an automatic ceiling for all subcomponents.

6. Missing internal deadlines. The due date on the NOFO is hard; no late submissions are accepted.

7. Weak application continuity narrative. If you had Phase II success, show progression. If you are resubmitting, explain exactly what changed and why this revision increases competitiveness.

8. Assuming this is a public-private matching substitute. The NOFO is not designed as a soft funding instrument; it requires hard commitments and strong accountability planning.

Practical submission checklist

Before submission, run through this checklist:

• Confirm participation in the relevant NIH component(s).
• Verify current SBIR/STTR Phase II status and award number, including expiration.
• Draft commercial value chain from pilot to patient/market outcome.
• Finalize 100% match package and source details.
• Verify registration status in NIH/Grants systems and technical portals.
• Confirm budget against IC table and statutory caps.
• Prepare SBIR/STTR information form with commercialization and finance sections completed.
• Prepare reviewer-ready response for compliance questions and potential JIT follow-up.
• Build internal deadline plan with at least 7 business days buffer before NIH due date.

This process is repetitive by design because NIH review is strict on missing form fields and non-responsive materials. The cleanest way to manage risk is to build your submission packet around checklist compliance first, narrative quality second.

FAQs for a first-time Phase IIB filer

Are clinical trials allowed?

They are listed as optional in general, but some participating NIH components (including NCATS and ORIP in this call) do not accept trial work under this NOFO. You need an IC-specific match.

Is this a grant or a contract?

The NOFO describes it as a grant (SBIR Phase IIB) with fixed funding and budget limits.

Do I need match for the full amount?

The NOFO says applicants must demonstrate not less than 100% matching funds. Plan to show this clearly in your finance and support narrative.

Can this be my first NIH small-business application?

No. This call is for former SBIR/STTR Phase II recipients and is positioned as a second-phase bridge mechanism.

How often can we apply?

There are recurring due dates in the NOFO table. The first available due date after posting is September 5, 2026, and multiple future cycles are listed through 2029. However, eligibility and matching readiness should determine which cycle you choose.

Is there an explicit cap on number of applications?

The solicitation points to the eligibility section for application limits and does not define a simple public cap at the top level. Practical constraints come from internal NIH/IC capacity and appropriations.

Risks to monitor after submission

Because this is a large federal opportunity, risk does not end at submission:

• If matching commitment weakens, NIH may ask for corrections through due-process channels.
• If your assigned IC has strict mission mismatch, reviewer routing can weaken even strong technical quality.
• If your commercial assumptions are not supported by evidence, your proposal may be viewed as “development intent only.”

Prepare your post-submission evidence index early: budget breakdown, match letters, technical rationale, commercialization milestone map, and continuity with Phase II outputs.

Why this matters strategically

For U.S. biomedical small businesses in advanced development, this NOFO fills a rare function: follow-on public support after Phase II when private finance is not yet sufficient but regulatory/prototyping/commercialization risks still require capital. If your company is still at feasibility stage, your effort should go to earlier SBIR/STTR mechanisms or commercialization pilots. If you are in this post-Phase-II stage and already have a concrete path to product readiness, this is one of the strongest NIH options currently visible in 2026.

Official links

• Official PA-27-101 NOFO (official source): https://files.simpler.grants.gov/opportunities/a44b38f2-6d15-4b5b-b1df-788a730bb203/attachments/ade120a7-9eae-4ae7-9ef3-e6f1d5d9ff19/PA-27-101-Full-Announcement.html
• NIH grants application guide: https://grants.nih.gov/grants/how-to-apply-application-guide
• NIH SBIR/STTR Program: https://seed.nih.gov
• NIH Policy Notices: https://grants.nih.gov/funding/nih-grants-and-cooperative-agreements/policy-notices